Merrimack Pharmaceuticals, Inc. announced today that the design of their Phase 1/2 trial investigating the safety and tolerability of MM-111 in HER2 positive cancer patients will be presented at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 4-8, 2010, in Chicago, Illinois.
MM-111 is a bi-specific antibody designed to specifically inhibit ErbB3 (HER3) signaling in ErbB2 (HER2) over expressing cancer cells. MM-111 binds to the critical ErbB2/ErbB3 cell receptor signaling complex and disables it from activating pAKT, an important mediator of cancer cell survival.
The poster is being presented in the Trials in Progress Poster Session by Crystal Denlinger, M.D., a medical oncologist at Fox Chase Cancer Center. This session is new to the ASCO meeting this year and is meant to facilitate awareness of and dialogue about open, ongoing clinical trials. The abstract can be accessed through the ASCO website, http://www.asco.org, and the abstract title and session time are provided below. The poster will be available after it is presented on Merrimack's website at http://www.MerrimackPharma.com.
Nanomedicine using gas bubbles offers hope for lung cancer treatment